The Regulatory Pendulum Swings In Favor Of Antibiotics, But Will Investments Follow?
This article was originally published in Start Up
Executive Summary
New incentives under the US government’s GAIN Act and FDA’s openness to faster development are helping put antibiotics back on investors’ radar screens, if not yet loosening their checkbooks.